Latest News

Memphis, TN – Scientists from St. Jude Children’s Research Hospital, Seattle Children’s and the Children’s Oncology Group (COG) have identified novel genetic variations that influence relapse risk in children with standard risk B-cell acute lymphoblastic leukemia (SR B-ALL), the most common childhood cancer. The identification of genomic predictors of relapse...
Ulsan, South Korea – A groundbreaking study conducted by Professor Jiyoung Park and her research team in the Department of Biological Sciences at UNIST has identified FAM3C, a metabolism-regulating signaling molecule produced by cancer-associated adipocytes (CAAs), as a key regulator of breast cancer progression within the tumor microenvironment (TME). The...
New York, NY – Addressing Brain Health in Adults With Intellectual Disabilities and Developmental Disabilities: A Companion to the KAER Toolkit for Primary Care Providers is a new publication from the Gerontological Society of America (GSA) designed to address the needs of adults with intellectual and developmental disabilities (I/DD) who...
ARLINGTON HEIGHTS, Ill. — Two new practice parameters from the Joint Task Force for Practice Parameters (JTFPP) offer evidence-based recommendations for the diagnosis and management of anaphylaxis and atopic dermatitis (AD) in pediatric and adult patients. The Joint Task Force is a partnership between the American College of Allergy, Asthma...
Hunter researchers have helped to discover two more genes that have been linked to the development of multiple sclerosis (MS). The research, published in this week’s international scientific journal Nature Genetics, provides clues to the causes of MS. The discovery was made by the ANZgene consortium which is made up...
CHATHAM, NJ – Tonix Pharmaceuticals, Inc. (NASDAQ:TNXP) appears to have a potential new weapon against fibromyalgia for the 6-12 million adults in America suffering from its debilitating effects. It has to do with sleep quality, not sleep quantity. Tonix’s candidate drug TNX-102 SL*, which just completed its second successful Phase 3...